

# NGL Fine-Chem Limited

Regd. Office : 301, E - Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, INDIA.  
Tel.: 022-40842222, 26108030, Email : info@nglfinechem.com, CIN : L24110MH1981PLC025884, Website : www.nglfinechem.com

November 10, 2021

To,  
Department of Corporate Service (DCS-CRD),  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai — 400 001.

**Sub: Outcome of the Board Meeting Dated 10<sup>th</sup> November, 2021.**  
**Scrip Code: 524774**

Dear Sir/Madam,

This is to inform you that the Third Meeting of the Board of Directors of NGL Fine-Chem Limited for the Financial Year 2021-2022 held on Wednesday, 10<sup>th</sup> November, 2021 at 301 E-Square, Subhash Road, Vile Parle East, Mumbai 400057 approved the following:

- 1) Approved Unaudited Standalone & Consolidated Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) Approved Cash Flow Statement for the half year ended on 30<sup>th</sup> September, 2021.
- 3) Approved Statement of Assets & Liabilities for the half year ended on 30<sup>th</sup> September, 2021.

We also enclose herewith the Limited Review Report on Standalone and Consolidated Financial Results issued by the Statutory Auditors of the Company.


The aforesaid results are also being disseminated on Company's website at [www.nglfinechem.com](http://www.nglfinechem.com).

The meeting of the Board of Directors commenced at 5.00 p.m. and concluded at 6.00 p.m.

Kindly take the same on your record.

Thanking you,

Yours faithfully,  
For NGL Fine-Chem Limited



Pallavi Pednekar  
Company Secretary & Compliance Officer  
Membership No: A33498





# MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

3, Shanti Kunj, 17, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 2618 5110

# 2618 5137

shailesh.manek@gmail.com

shailesh@camanek.com

www.camanek.com

**SHAILESH MANEK**  
B.Com.(Hons), Grad. C.W.A.,F.C.A.  
Cell: +91 93222 26311

**MITTUL DALAL**  
B.Com. A.C.A  
Cell: +91 80973 74277

Review report to  
The Board of Directors,  
**M/s.NGL Fine-Chem Limited**

We have reviewed the accompanying statement of unaudited financial results of **M/s.NGL Fine-Chem Limited** for the period ended **September 30, 2021**.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MANEK & ASSOCIATES**  
**Chartered Accountants**  
Firm's Registration No.:126679W



MUMBAI  
Dated: **10/11/2021**

*Shailesh Manek*  
(SHAILESH MANEK)

Partner  
Membership Number:034925  
UDIN: **21034925AAAALD8235**



# MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

3, Shanti Kunj, 17, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 2618 5110

# 2618 5137

shailesh.manek@gmail.com

shailesh@camanek.com

www.camanek.com

**SHAILESH MANEK**

B.Com.(Hons), Grad. C.W.A., F.C.A.

Cell: +91 93222 26311

**MITTUL DALAL**

B.Com. A.C.A

Cell: +91 80973 74277

## Independent Auditor's Review Report

To,  
The Board of Directors,  
**M/s.NGL Fine-Chem Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **M/s.NGL Fine-Chem Limited** ("the Parent") and its subsidiary **M/s.Macrotech Polychem Private Limited** (the Parent and its subsidiary together referred to as "the Group", and its share of the net profit/loss) after tax and total comprehensive income/loss of its associates and joint ventures for the quarter ended **30<sup>th</sup> September 2021** and for the period from **01<sup>st</sup> July 2021** to **30<sup>th</sup> September 2021** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

# MANEK & ASSOCIATES

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of M/s.Macrotech Polychem Private Limited, its wholly owned subsidiary.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MANEK & ASSOCIATES**  
**Chartered Accountants**  
Firm's Registration No.:**126679W**



*Shailesh Manek*  
**(SHAILESH MANEK)**

Partner

Membership Number:**034925**  
UDIN: **21034925AAAAL3462**

MUMBAI

Dated : **10/11/2021**

# NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road  
Vile Parle ( East), Mumbai 400 057  
CIN: L24110MH1981PLC025884



## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER 2021

### Part I: Statement of Consolidated and Standalone Unaudited Results for the Quarter and Half Year ended 30th September 2021

Rupees in lakhs

Particulars	Consolidated						Standalone					
	Quarter Ended		Half Year Ended		Year Ended		Quarter Ended		Half Year Ended		Year Ended	
	30.09.2021 (Unaudited)	30.06.2021 (Unaudited)	30.09.2021 (Unaudited)	30.09.2020 (Unaudited)	30.09.2021 (Unaudited)	31.03.2021 (Audited)	30.09.2021 (Unaudited)	30.09.2021 (Unaudited)	30.09.2021 (Unaudited)	30.09.2021 (Unaudited)	30.09.2021 (Unaudited)	31.03.2021 (Audited)
I Revenue from Operations	7,836.59	7,586.28	15,422.87	6,834.39	11,065.71	25,797.48	7,849.72	7,590.88	6,820.72	15,440.60	11,063.08	25,520.76
II Other Income	438.38	455.05	894.43	276.46	495.08	801.75	493.68	492.23	285.40	980.91	510.66	1,152.09
III Total Revenue (III)	8,275.97	8,041.33	16,317.30	7,110.85	11,560.79	26,599.23	8,338.40	8,083.11	7,106.12	16,421.51	11,573.74	26,672.85
IV Expenses :												
a) Cost of Material Consumed	4,713.03	3,433.30	8,146.33	2,936.21	4,701.79	-0,048.25	4,751.42	3,411.25	2,942.57	8,162.67	4,714.57	10,083.96
b) (Increase)/Decrease in stock in trade and work in progress	-1,200.30	-207.68	(1,407.98)	53.99	(25.71)	186.12	(1,200.30)	(207.68)	53.99	(1,407.98)	(25.71)	186.12
c) Employee benefits expenses	910.76	746.10	1,656.87	719.98	1,259.88	2,809.28	870.72	718.92	699.07	1,589.65	1,227.27	2,723.50
d) Finance Costs	40.21	37.01	77.22	54.38	114.53	184.01	40.21	37.01	54.38	77.22	114.53	184.01
e) Depreciation and amortisation expenses	219.82	217.81	437.63	205.21	414.84	833.40	195.55	183.34	181.42	388.89	368.10	739.40
f) Other expenses	1,696.79	1,257.89	2,954.67	1,083.86	1,747.23	4,779.21	1,773.21	1,355.71	1,253.12	3,128.92	2,015.74	5,176.15
Total Expenses (IV)	6,380.31	5,484.43	11,864.74	5,053.63	8,212.56	8,840.27	6,430.81	5,508.55	5,184.55	11,938.37	8,414.50	19,073.14
V Profit/(loss) before exceptional items and tax (III-IV)	1,895.66	2,556.90	4,452.55	2,057.22	3,348.23	7,758.95	1,907.59	2,574.56	1,921.57	4,482.14	3,159.24	7,599.71
VI Exceptional Items	-	-	-	-	-	-	-	-	-	-	-	-
VII Profit/(loss) Before Tax (V-VI)	1,895.66	2,556.90	4,452.55	2,057.22	3,348.23	7,758.95	1,907.59	2,574.56	1,921.57	4,482.14	3,159.24	7,599.71
VIII Tax Expense												
a) Current Tax	(456.60)	(605.50)	(1,062.10)	(474.30)	(762.60)	1,943.00	(440.00)	(600.00)	(443.00)	(1,040.00)	(728.00)	(1,912.00)
b) MAT Tax	-	-	-	-	-	-	-	-	-	-	-	-
b) Prior Years	(47.68)	(38.82)	(86.50)	(3.62)	(69.71)	-143.72	(48.69)	(39.69)	(3.90)	(88.38)	(71.29)	(145.80)
c) Deferred Tax	1,391.38	1,912.58	3,303.95	1,580.79	2,517.41	5,671.89	1,418.90	1,934.87	1,479.72	3,353.76	2,365.00	5,546.96
Other Comprehensive Income												
a. Gain/(Loss) on actuarial valuation of post employment benefits	(26.14)	2.10	(24.04)	(21.22)	(25.96)	-18.82	(25.97)	2.12	(21.30)	(23.85)	(25.91)	(18.81)
b. Deferred tax on above	6.57	(0.53)	6.05	5.34	6.51	4.74	6.53	(0.54)	5.36	6.00	6.52	4.73
c. Other Comprehensive Income (Net of Tax)	(19.57)	1.57	(17.99)	(15.88)	(19.35)	-14.08	(19.44)	1.58	(15.94)	(17.85)	(19.39)	(14.08)
Total Comprehensive Income	1,371.81	1,914.15	3,285.96	1,564.91	2,498.06	5,657.81	1,398.46	1,936.45	1,463.78	3,335.91	2,345.61	5,532.88
XII Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90
XXIII Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	N.A	N.A	-5,136.88	N.A	N.A	N.A	N.A	N.A	15,236.36
XIV Earnings Per Share (EPS)												
a) Basic	22.52	30.96	53.48	25.59	40.75	91.81	22.97	31.32	23.95	54.29	38.28	89.79
b) Diluted	22.52	30.96	53.48	25.59	40.75	91.81	22.97	31.32	23.95	54.29	38.28	89.79



# NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road  
Vile Parle ( East), Mumbai 400 057  
CIN: L24110MH1981PLC025884

## Part II: Statement of Consolidated and Standalone Assets and Liabilities as on 30th September 2021

PARTICULARS	Rupees in lakhs			
	Consolidated Statement of Assets & Liabilities		Standalone Statement of Assets & Liabilities	
	Rupees in Lakhs		Rupees in Lakhs	
	As at half year ended 30.09.2021	As at year ended 31.03.2021	As at half year ended 30.09.2021	As at year ended 31.03.2021
	UN-AUDITED	AUDITED	UN-AUDITED	AUDITED
<b>ASSETS</b>				
<b>1. Non-current assets</b>				
(A) Property, Plant and Equipment	6,337.56	6,362.43	5,707.91	5,717.90
(B) Capital work-in-progress	2,423.27	1,235.15	172.18	90.97
(C) Investment Property				
(D) Goodwill	15.27	15.27	-	-
(E) Other Intangible assets	27.59	34.96	27.59	34.96
(F) Intangible assets under development				
(G) Biological Assets other than bearer plants				
(H) Financial Assets				
(i) Investments			372.51	372.51
(ii) Trade receivables				
(iii) Loans			2,767.08	1,537.22
(iv) Others			714.71	714.71
(I) Deferred tax assets (net)	720.35	720.35		
(J) Other non-current assets	128.57	212.48	92.99	59.42
<b>2. Current assets</b>				
(A) Inventories	5,475.27	3,785.05	5,475.27	3,785.05
(B) Financial Assets				
(i) Investments	3,917.42	2,907.01	3,917.42	2,907.01
(ii) Trade receivables	5,765.42	3,755.74	5,765.42	3,755.74
(iii) Cash and cash equivalents	61.31	210.33	59.39	203.20
(iv) Bank balances other than (iii) above	12.86	10.76	9.61	9.61
(v) Loans				
(vi) Others	529.94	303.62	508.50	309.17
(C) Current Tax Assets (Net)	1,275.07	1,223.40	1,004.37	1,120.08
(D) Other current assets				
<b>Total Assets</b>	<b>26,689.90</b>	<b>20,776.55</b>	<b>26,594.92</b>	<b>20,617.55</b>
<b>EQUITY AND LIABILITIES</b>				
<b>1. Equity</b>				
(A) Equity Share capital	308.90	308.90	308.90	308.90
(B) Other Equity	18,314.72	15,136.68	18,464.16	15,236.36
<b>2. Liabilities</b>				
(I) Non-current liabilities				
(A) Financial Liabilities				
(i) Borrowings	422.61	613.13	422.61	613.13
(ii) Trade payables				
(iii) Other financial liabilities				
(B) Provisions	275.43	246.05	271.20	243.24
(C) Deferred tax liabilities (Net)	318.22	237.77	320.08	237.70
(D) Other non-current liabilities	18.03	19.51	18.03	19.51
(II) Current liabilities				
(A) Financial Liabilities				
(i) Borrowings	1,497.42	483.17	1,497.42	483.17
(ii) Trade payables	4,644.02	2,953.40	4,419.03	2,698.00
(iii) Other financial liabilities	530.88	611.99	530.88	611.99
(B) Other current liabilities				
(i) Other current liabilities	0.24	0.21	0.24	0.21
(C) Provisions	63.53	62.91	63.22	62.69
(d) Current Tax Liabilities (Net)	295.99	102.62	279.15	102.62
<b>Total Equity and Liabilities</b>	<b>26,689.90</b>	<b>20,776.55</b>	<b>26,594.92</b>	<b>20,617.55</b>



# NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road  
Vile Parle ( East), Mumbai 400 057  
CIN: L24110MH1981PLC025884

## Part III: Consolidated and Standalone Cash Flow Statement for the half year ended 30th September 2021

Particulars	Consolidated Cash Flow		Standalone Cash Flow	
	For the half year ended 30th Sept 2021	For the year ended March 31, 2021	For the half year ended 30th Sept 2021	For the year ended March 31, 2021
Rupees in lakhs				
<b>A. Cash flow from operating activities</b>				
Profit before extraordinary items and tax	4,452.55	7,758.95	4,482.14	7,599.71
Adjustments for:				
Depreciation and amortisation expense	437.63	833.40	388.89	739.40
Finance costs	77.22	184.01	77.22	184.01
Dividend income	-4.79	-0.48	-4.79	-0.48
Interest income	-8.65	-19.76	-95.33	-73.13
Gain on sale of investments	-421.00	-510.46	-421.00	-510.46
Other Comprehensive Income	-17.99	-14.08	-17.85	-14.08
Operating profit before working capital changes	4,514.77	8,231.59	4,408.28	7,924.98
Changes in working capital:				
Adjustments for (increase)/ decrease in operating assets:				
Inventories	-1,690.21	-995.37	-1,690.21	-995.37
Other non-current financial assets	-	-5.64	-	-
Other non-current assets	83.92	-168.77	-33.57	-34.54
Trade receivables	-2,009.68	-1,136.47	-2,009.68	-1,136.47
Other current financial assets	-1,238.84	-1,942.51	-1,210.19	-1,745.43
Other current assets	-51.66	-221.40	115.71	-133.93
	-4,906.48	-4,470.15	-4,827.94	-4,045.74
sub total				
Adjustments for increase/ (decrease) in operating liabilities:				
Trade payables	1,690.62	870.37	1,721.03	640.07
Other current financial liabilities	-81.12	-22.21	-81.12	-22.21
Other current provisions	0.62	-63.47	0.53	-63.60
Other current liabilities	193.29	102.65	176.55	102.65
Other non-current liabilities	78.97	138.41	80.89	140.48
Net Change in Reserves on Consolidation	29.38	35.29	27.96	33.53
Other non-current provisions				
(d) Current Tax Liabilities (Net)	1,911.77	1,061.02	1,925.85	830.90
sub total				
Cash generated from operations	1,520.06	4,822.46	1,507.19	4,710.15
Net income tax paid	-1,148.60	-2,087.06	-1,128.38	-2,052.75
Net cash flow from operating activities (A)	371.45	2,735.41	378.81	2,657.40
<b>B. Cash flow from investing activities</b>				
Gain on sale of investments	421.00	510.46	421.00	510.46
Dividend income	4.79	0.48	4.79	0.48
Fixed Deposit Matured	-	99.56	0.44	99.56
Interest Income	8.65	19.76	95.33	73.13
Finance Cost	-77.22	-184.01	-77.22	-184.01
Non-current investments				
Non-current Loans				
Long term borrowings	-190.52	-219.35	-1,228.85	-1,184.11
Short term borrowings	1,014.26	-976.91	1,014.26	-976.91
Purchases of Fixed assets	-1,659.30	-1,721.19	-518.52	-512.32
Loss of capital goods by fire				
Disposal of fixed assets	65.78	14.36	65.78	14.36
Net cash flow used in investing activities (B)	-412.36	-2456.85	-414.51	-2378.72
sub total				
<b>C. Cash flow from financing activities</b>				
Issue of Share Capital				
Dividend Payout				
Net cash flow from/ (used in) financing activities (C)	-108.12	-108.12	-108.12	-108.12
Net increase/ (decrease) in Cash and cash equivalents (A+B+C)	-149.02	170.44	-143.81	170.56
Add: Cash and cash equivalents at the beginning of the year	210.33	39.89	203.20	32.64
Cash and cash equivalents at the end of the year*	61.31	210.33	59.39	203.20

# NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road  
Vile Parle ( East), Mumbai 400 057  
CIN: L24110MH1981PLC025884

Particulars	For the half year ended 30th Sept 2021	For the year ended March 31, 2021	For the half year ended 30th Sept 2021	For the year ended March 31, 2021
Cash and cash equivalents at the end of the year*				
*Comprises of:				
(a) Cash on hand	21.38	16.93	20.33	16.86
(b) Balances with banks	39.93	193.40	39.06	186.24
(c) In current accounts	61.31	210.33	59.39	203.20

#### Notes:

- 1 The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 10th November, 2021. These results are subjected to Limited Review by the Statutory Auditors of the Company.
- 2 The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- 3 The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrotech Polychem Private Limited.
- 4 Previous period figures have been regrouped/rearranged wherever necessary.

Place: Mumbai  
Date: 10-Nov-21

**Rahul Jayant Nachane**  
Digitally signed by  
Rahul Jayant  
Nachane  
on behalf of  
NGL Fine Chem  
Ltd  
Date: 2021.11.10  
18:19:06 +05'30'

**Rahul Nachane**  
Managing Director